Roivant Sciences Ltd. (ROIV)

Roivant Sciences' stock price has increased by approximately 148.76% over the last 12 months, though it experienced a 4.67% decrease in the past month (as of March 24, 2026). Key events include Q2 2025 earnings on November 10, 2025, and Q3 2025 earnings on February 6, 2026. Roivant held an Investor Day on December 11, 2025. On March 3, 2026, Roivant announced a $2.25 billion global settlement with Moderna. Positive Phase 3 VALOR trial results for brepocitinib in dermatomyositis were published on March 28, 2026, and the FDA granted Priority Review for the NDA on March 3, 2026. Positive Phase 2 results for brepocitinib in cutaneous sarcoidosis were announced on February 6, 2026. Bernstein initiated coverage with an "Outperform" rating on March 20, 2026, and other analysts have reiterated "Buy" ratings.

The demand for pharmaceutical products can exhibit seasonality, influenced by factors such as weather changes, allergy seasons, and the prevalence of infectious diseases. However, given Roivant Sciences' diverse pipeline spanning multiple therapeutic areas, a single, overarching seasonal demand pattern for all its products is unlikely. The seasonality of demand would likely vary significantly depending on the specific indication and therapeutic area of each individual product.

Roivant Sciences is a biopharmaceutical company that uses its "Vant" model to develop and commercialize transformative medicines. The company in-licenses promising drug candidates and establishes specialized subsidiary companies, known as "Vants," each dedicated to a particular therapeutic area. Its pipeline includes product candidates across immunology, oncology, hematology, dermatology, and pulmonary diseases, such as Vtama for plaque psoriasis, batoclimab for IgG-mediated autoimmune indications, brepocitinib for dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis, IMVT-1402 for autoimmune diseases, namilumab for inflammatory disorders, mosliciguat for pulmonary hypertension, and RVT-2001 for various illnesses. Roivant also incubates discovery-stage companies and health technology startups, such as Datavant and Lokavant.

Roivant Sciences is headquartered in London, United Kingdom, with major offices in New York City, United States, and Basel, Switzerland. The company's shares are traded on the Nasdaq Global Select exchange in the US, and also on several European exchanges including Frankfurt, Munich, Stuttgart, Dusseldorf, and Berne.

Roivant Sciences' brand reputation appears to be largely positive, driven by clinical advancements and strategic financial moves. Positive Phase 3 trial results for brepocitinib and the FDA's priority review enhance the company's scientific credibility. The $2.25 billion settlement with Moderna reflects a favorable outcome in intellectual property matters. Analyst firms have initiated or reiterated positive ratings with increased price targets. Recent events have focused on positive developments, despite a past accusation related to a former subsidiary.

Roivant Sciences has a mixed ownership structure, including institutional, insider, and retail investors. As of December 2025, 374 institutions held a collective 69.3% of the stock, with major shareholders including Fmr Llc, Morgan Stanley, Vanguard Group Inc, and BlackRock, Inc. Insiders collectively own about 20.20% to 27.97% of the company's stock. Vivek Ramaswamy, the founder, held a 10.5% stake as of March 31, 2024. Other significant individual and insider owners include Daniel Allen Gold and Dexcel Pharma Technologies Ltd. QVT Financial LP is also listed as a large individual shareholder.